Control Print Q2 FY27 Earnings Call — Analysis (NSE: CONTROLPR)
Control Print delivered 28.6% YoY consolidated revenue growth in Q2FY27 to ₹144 Cr while subsidiary losses narrowed sequentially to ₹5 Cr amid ongoing restructuring at V-Shapes.
Result quality: watch — Margin pressure. Management sentiment: optimistic.
The take
Q2FY27 Consolidated Operating Revenue ₹144 Cr ( +28.57% YoY ) . New guidance — core coding and marking margin… 60% gross profit and about 30% EBIT . New story: V-Shapes IP and Turnaround .
Results
Consolidated operating revenue grew 28.6% YoY to ₹144 Cr in Q2FY27, with standalone operating revenue reaching ₹131 Cr (+31% YoY).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Operating Revenue | ₹144 Cr | +28.57% | yoy · Q2FY27 · vs ₹112 Cr in Q2FY26 |
| Standalone Operating Revenue | ₹131 Cr | +31.00% | yoy · Q2FY27 · vs ₹100 Cr in Q2FY26 |
| Standalone Operating Revenue | ₹235 Cr | +16.34% | yoy · H1FY27 · vs ₹202 Cr in H1FY26 |
| Standalone Total Revenue | ₹134 Cr | none · Q2FY27 · reported standalone total revenue | |
| Standalone Total Revenue | ₹241 Cr | none · H1FY27 · reported standalone total revenue | |
| Subsidiary PBT Loss | ₹5 Cr | -37.50% | sequential · Q2FY27 · vs ₹8 Cr in Q1FY27 and ₹12 Cr in Q4FY26 |
| Standalone Cost of Goods Sold | 41.65% | -67bps | sequential · Q2FY27 · as % of operating revenue vs 42.32% in Q1FY27 |
| Consolidated Cost of Goods Sold | 44% | +400bps | yoy · Q2FY27 · as % of operating revenue vs 40% in Q2FY26 |
Guidance
Management targets long-term core coding and marking margins of 60% gross profit and 30% EBIT while guiding for CP MEA subsidiary breakeven/profitability within FY27.
What management committed to
- Target about 60% gross profit and about 30% EBIT in [Control Print's] core coding and marking business. — 60% gross profit and about 30% EBIT, target for core business
- [CP MEA Middle East subsidiary] will definitely be a profitable entity / break even by the year end [FY27]. — break even / profitable, Q4FY27
- [Control Print's] Track & Trace segment has got a good pipeline of orders and delivery will be in the next two quarters [Q3FY27-Q4FY27]. — Q4FY27
- Target is to finish [V-Shapes machine redesign and blueprint project] in January or February [2027]. — Q4FY27
Key themes
Core scaling alongside subsidiary restructuring
How the narrative shifted
- V-Shapes IP and Turnaround: Management views V-Shapes as an IP-protected packaging platform requiring upfront technology gestation and restructuring rather than a conventional loss-making subsidiary.
- Core Coding and Marking Steady Cash Engine: The domestic oligopolistic coding and marking franchise continues to generate solid operating cash flows, funding expansion into new technology platforms.
- Regulatory Tailwinds in Track & Trace: Upcoming pharmaceutical regulatory mandates expanding from 300 to 1,000 brands by 2027 and broader categories in 2028 will expand addressable TAM.
- Overseas Subsidiary Rationalisation: Headcount rationalisation and fixed-cost reduction across European acquisitions are driving sequential reductions in consolidated subsidiary losses.
Operational commentary
- Coding and marking division accounted for 94-95% of total operating revenue with steady demand across pipes, food, dairy, cable, wire, FMCG, steel, and wood verticals.
- V-Shapes restructuring underway: replaced 65-70% of Italian operational staff with contract personnel, reduced base costs by 25%, and boosted sales team from zero to three members.
- V-Shapes machine retrofits and redesign testing targeted for completion by Jan-Feb 2027 to establish blueprint for new manufacturing batches.
- Government-mandated Track & Trace regulations gazetted for top 1,000 brands (expected 2027) and anti-infectives/vaccines (expected 2028), expanding total addressable domestic market beyond current ₹600-700 Cr.
- Guwahati Unnati capex project temporarily suspended due to program incentive exhaustion; company relocated equipment to two temporary manufacturing sites.
Analyst Q&A
Q. What is the timeline and capital loss threshold for turning around or divesting the loss-making V-Shapes subsidiary?
Management defended V-Shapes as a long-term IP-driven technology investment creating a defensible patent moat, stating execution is improving despite lagging numbers and declining to give an exit timeline or loss cap.
Q. Can management provide a company-wise breakup of losses across international subsidiaries (Markprint, Codeology, CP Italy)?
Declined to disclose company-wise breakdown over the call, citing company policy, but offered to share details offline at their Mumbai office while confirming Markprint is profitable and MEA is near breakeven.
Q. What is the market size and expected timeline for pharmaceutical Track & Trace expansion?
Market is currently ₹600-700 Cr on the top 300 mandated brands; next regulatory phases covering 1,000 brands (2027) and anti-infectives/vaccines (2028) will expand total TAM substantially.
Research and educational content only. Not investment advice.